Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Trial Parameters
Brief Summary
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years, * Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min), * Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria), * Stable standard therapy for at least three months prior to inclusion in the study. Exclusion Criteria: * Kidney donor or recipient, * Active malignancy, * Pregnancy or breastfeeding, * Known intolerance or hypersensitivity to VPN, * Participation in other interventional trials, * Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits), * Patients with severe comorbidities * Patients receiving warfarin